Get the Stockscreener App
47.17
0.84%
-0.40
After Hours:
47.78
0.61
+1.29%
Guardant Health Inc stock is traded at $47.17, with a volume of 1.33M.
It is down -0.84% in the last 24 hours and up +39.72% over the past month.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$47.57
Open:
$48.45
24h Volume:
1.33M
Relative Volume:
0.65
Market Cap:
$5.83B
Revenue:
$692.26M
Net Income/Loss:
$-512.41M
P/E Ratio:
-11.12
EPS:
-4.24
Net Cash Flow:
$-274.36M
1W Performance:
-2.26%
1M Performance:
+39.72%
6M Performance:
+48.57%
1Y Performance:
+112.57%
1-Day Range:
$46.84
$48.45
1-Week Range:
$44.10
$50.89
52-Week Range:
$15.81
$50.89
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
47.17 | 5.83B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
580.57 | 222.07B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
215.01 | 154.61B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
147.04 | 41.95B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
465.03 | 38.08B | 3.84B | 866.24M | 792.60M | 10.37 |
|
IQV
Iqvia Holdings Inc
|
200.04 | 36.31B | 15.32B | 1.41B | 1.96B | 7.62 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Guardant Health (NASDAQ:GH) Sets New 12-Month HighWhat's Next? - MarketBeat
Guardant Health (NASDAQ:GH) Trading Down 5.7%Should You Sell? - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Shares Sold by SG Americas Securities LLC - MarketBeat
Why Guardant Health, Inc. (GH) Is Among the Best Booming Stocks to Invest in Now? - Insider Monkey
Exchange Traded Concepts LLC Decreases Stock Position in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
12 Best Booming Stocks to Invest in Now - Insider Monkey
The Goldman Sachs Group Raises Guardant Health (NASDAQ:GH) Price Target to $49.00 - MarketBeat
Guardant Health (NASDAQ:GH) Given New $49.00 Price Target at The Goldman Sachs Group - MarketBeat
Abu Dhabi selects Guardant Health’s Shield Test for blood-based colorectal cancer screening programme - BSA bureau
Guardant Health stock soars to 52-week high of $49.97 - MSN
Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025 - Milton Daily Standard
Guardant Health stock soars to 52-week high of $49.97 By Investing.com - Investing.com Nigeria
Guardant Health Selected by Abu Dhabi Health Department to Launch Colorectal Cancer Screening Program - Marketscreener.com
Guardant Health Secures Landmark Deal: 10,000 Cancer Screenings Set for Abu Dhabi - StockTitan
Okla And Rigetti Computing Are Among Top 8 Mid Cap Gainers Last Week (Jan 20-Jan 24): Are The Others In Your Portfolio? - Benzinga
Why Guardant Health (GH) Is Skyrocketing Now - Insider Monkey
Guardant Health (NASDAQ:GH) Stock Price Up 6.4%What's Next? - MarketBeat
Guardant Health stock target raised to $55 by BTIG - MSN
Barclays Initiates Coverage of Guardant Health (GH) with Overweight Recommendation - MSN
Leerink Partnrs Weighs in on Guardant Health Q4 Earnings - Defense World
Barclays initiates Guardant Health stock with Overweight rating By Investing.com - Investing.com Canada
Guardant Reveal aids organ preservation in rectal cancer treatment - Investing.com India
Barclays Begins Coverage on Guardant Health (NASDAQ:GH) - MarketBeat
Barclays initiates Guardant Health stock with Overweight rating - Investing.com
Q4 EPS Estimate for Guardant Health Increased by Analyst - MarketBeat
Guardant Health to Present Major Cancer Detection Breakthroughs at ASCO GI 2025 Symposium - StockTitan
Why Guardant Health, Inc. (GH) Soared At The Start Of The Trading Week - MSN
Guardant Health (NASDAQ:GH) Shares Up 6.4%Here's Why - MarketBeat
Guardant Health's (GH) "Buy" Rating Reaffirmed at Guggenheim - MarketBeat
Guardant Health stock hits 52-week high of $39.61 amid growth - Investing.com Australia
Wealthcare Advisory Partners LLC Takes $252,000 Position in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 43% Share Price Bounce - Simply Wall St
Guardant stock jumps 12% on Medicare coverage expansion - MSN
Guardant Health director Tariq Musa sells shares worth $4,359 - MSN
Raymond James maintains Outperform on Guardant Health, $39 target - MSN
Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone - MSN
Why This Top 4% Cancer-Tied Stock Just Hit A 13-Month High - Investor's Business Daily
Canaccord maintains Guardant Health stock Buy rating and $42 target - MSN
Guardant Health Gains Medicare Coverage For Colorectal Cancer Monitoring Test - Yahoo Finance
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.26%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):